With complete remission success rates of up to 85% in blood cancer patients, chimeric antigen receptor T-cell (CAR-T) therapies have transformed cancer care since 2017, when Novartis AG’s Kymriah (tisagenlecleucel) became the first CAR-T to secure authorization from the US Food and Drug Administration.
There are now six CAR-T therapies authorized in the US, EU, and many other countries worldwide (see Exhibit 1). But...